|

Serplulimab Clinical Trials

26 actively recruiting trials

Also known as: Carboplatin, Cisplatin, Concurrent radiotherapy Maintenance therapy, Etoposide, HLX-10LX +4 more

Pipeline

Phase 2: 22Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Fudan University4
  • Tianjin Medical University Cancer Institute and Hospital2
  • Sun Yat-sen University2
  • Shanghai Henlius Biotech2
  • Henan Cancer Hospital2

Indications

  • Cancer26
  • Lung Cancer6
  • Gastric Cancer3
  • Non Small Cell Lung Cancer3
  • Liver Disease2

Other26 trials

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Phase 2
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Phase 1/2
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
Phase 2
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Phase 2
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Phase 2
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
N/A
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Phase 2
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Phase 2
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Phase 2
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 2/3
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Phase 2
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
Phase 2
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2
Serplulimab Combined With CCRT for LS-SCLC.
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Phase 2
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Phase 2
Serplulimab for Locally Advanced Cervical Cancer
Phase 2
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Phase 2
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Phase 2
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.